The section describes the attributes used in the definition of the concepts classes in the national extension model. Descriptions of the attributes used in both the international content and the national extension are given in the international Medicinal Product Hierarchy Specification.

Has product name

Definition

: The (authorised) product name for the medicinal product as designated by the license holder (supplier); this may (or may not) be a trademarked name, and is often referred to as the "brand name".  brand name. 

Discussion

The 

It is not essential that the product name be an invented or brand name - ; it can be a generic name if extensions choose to follow the pattern shown in Figure 4 above(for example, using one or more international non-proprietary therapeutic substance names). The product name concepts are authored to value the definitional attribute for the real medicinal products and real clinical drugs in the national extension as required by the use cases for that extension. This means that for those extensions that wish , and since real packaged clinical drugs contain real clinical drugs, this set of concepts does also. 

It is possible for an extension that wishes to author a hierarchy of product name concepts , they can to choose to value the has the 

For example:

Image Removed

,

Figure 46Figure 23: Diagram of examples of a product name hierarchy

In a product name hierarchy, the parent product name concept should be authored to authored to reflect the unique set of active ingredient substances for the Real Medicinal Product (see the brand family example in Figure 6 above) and associated Real Clinical Drug and Real Packaged Clinical Drug concepts. It should therefore not include real medicinal product and associated real clinical drug concepts.  It is therefore most useful if the parent product name does not include any reference to dose form (e.g., "LA" or "Retard") or to strength (e.g., "Double Strength" of "for Children") or any other information such as indication (e.g., "Shingles Treatment").  Child product name concepts can be authored to include additional information as provided in the authorised name for Real Clinical Drugs and/or Real Packaged Clinical Drugsreal clinical drugs.  

Product name concepts must be authored in each national extension since the same product name can represent products containing different active ingredients in different jurisdictions, and therefore, the product name has can have a different meaning in different jurisdictions. 

The "has The 774158006 |Has product name " (attribute)| is available from the Concept concept model attribute hierarchy; values for the "has for 

Has supplier

Definition

The : the (name of the) organisation that holds the authorisation for marketing or supply of the medicinal product. 

Discussion

The 

Medicinal products, like other complex products, are rarely "manufactured" by one single organisation; the substances in a product , including active ingredient substance may be sourced from a range of specialist manufacturers and then assembled into the manufactured dose form by another organisation. The assembling organisation may be a contract manufacturer holding a manufacturing license and working for a variety of clients.  In ISO 11615:2017, the "manufacturer" of a medicinal product is defined as the "organisation that holds the authorisation for the manufacturing process", and it notes that "establishment is a synonym of manufacturer"; establishment .  Establishment is a term that is often used in the USA.  In national terminologies for clinical use, however, the term "manufacturer" usually refers to the organisation whose name and details are associated with the professional and public facing information about the product.  This To avoid confusion in this specification, the term manufacturer has not been used; instead , supplier is the term used and is the organisation responsible for providing the clinical information to support the product use ( both for patients and healthcare professionals ) and is also responsible for the quality and safety of the product, including for managing management of all adverse event information relating, or possibly relating to, the product in use.  All of those are the responsibility of the organisation that is authorised to supply the product into the supply chain.  Some healthcare cultures allow agreements whereby an organisation may obtain supplies stocks of a medicinal product and then to re-package or re-label repackage or relabel that medicinal product and place it into the supply chain, either within a single jurisdiction , or across a group of jurisdictions.  In this case, the repackaging/relabeling organisation is acting as a supplier, and their name and details are likely to be present on the packaging, either exclusively or in addition to the primary organisation.   In these cases, the responsibility for the product information and the product quality and safety is shared in various ways depending on the agreement and jurisdictional regulations.

Nations/affiliates will need to must decide the principles under which they will to populate the manufacturer/ 774159003 |Has supplier (attribute)|, based on their own regulations and context of practice. The simplest rule is to use the company who holds the authorisation to market the medicinal product, ; but , as described above, there can be complexities. 

Issues to consider are:

• whether re-packaging or re-labelling Whether repackaging or relabeling is allowed by regulation and whether this is internal to the jurisdiction (as in the USA) or external to the jurisdiction (sometimes known as " parallel importing" or sale of "grey products" in Europe) or whether both are allowed, and how the authorisations for these are managed and therefore which organisation (the licensed re-packager repackager or the marketing authorisation holder) to designate as the manufacturer/supplier
• the The role of the manufacturer/supplier information and the use case(s) to be supported, which may include
  • contact Contact for queries from clinicians and/or patients
  • pharmacovigilance Pharmacovigilance and product safety
• whether Whether the national medicines terminology will include medicines not authorised in their jurisdiction, and if so, how they wish to provide manufacturer/supplier information for these
  • for For medicinal products licensed outside the jurisdiction, reference to the manufacturer is still likely to be appropriate
  • for For compounded specials, to reference a generic "specials manufacturer" concept is possible since most of these will hold an authorisation to undertake specials manufacture

...

Due to the nature of the domain where either individual products or whole product sets, with their brand name and authorisation, can be sold from one organisation to another, it may be that even within one jurisdiction a single product name will be associated with more than one supplier.  In situations where individual Real Clinical Drugs (or Real Packaged Clinical Drugs, for those products authorised at that level) that For those extensions that populate the real medicinal product concept class, in situations where individual real clinical drugs share the same product name , but have different supplier organisations, two Real Medicinal Products real medicinal products will exist, as shown in the example below:

Image Removed

Figure 2447: Diagram to show RCDs sharing a single product name associated with different RMPs due to having different suppliers

The has supplier attribute will be The 774159003 | Has supplier (attribute) | is available from the Concept concept model attribute hierarchy; values for the Has Supplier attribute will be authored in the national extension, using the root of 77416004 .  Supplier organisations, by virtue of being corporate bodies and legal entities, are unique to a given nation and must have their representation authored within the national extension using 774164004 | Supplier (supplier) | from the Qualifier hierarchy.the Qualifier hierarchy as the root concept.

Count of clinical drug type

Definition

The number (count) of of distinct clinical drug (concepts) present in the package.  For all non-combination packages, this value should be "one".

Discussion

The 

Count attributes are used for all medicinal product and package concepts that must be represented using the closed world view as a proxy for and until a more expressive description logic becomes available to properly represent the universal restriction.  Packaged medicinal products must be described as containing only those clinical drugs that are stated in the logical definition; no other content is to be contemplated (no open world view).   A package containing 500mg paracetamol tablets must contain explicitly and only 500mg paracetamol tablets (not paracetamol capsules, or paracetamol and codeine tablets).  To correctly describe this, and particularly to ensure that pack concepts classify correctly, so that packs that contain more than one (type of) clinical drug (i.e. combination packs) do not classify as children of packs that contain only one type of clinical drug, it is necessary to use a clinical drug count.  This follows a similar pattern to the use of the active ingredient count attribute used for MP only concepts, MPF only concepts, and clinical drug concepts.   

By using a count attribute in the definition of closed world concepts, the count information is machine processable, and therefore if/when a more expressive description logic becomes available to properly represent the closed world view, then all the count attributes can be used to transfer to the closed world description logic consistently.

Standard packs containing a single clinical drug type have a count of "one" for the

Combination packs have the appropriate count (always greater than one) for the number of clinical drug types present in the combination pack.  If one of the components of a combination pack is a therapeutically inactive diluent, national extensions can choose whether to include this in the "count of clinical drug" and therefore whether the pack containing the diluent will classify as a sibling or as a child of any pack not containing a diluent. 

Contains clinical drug

Definition

The (real) clinical drug : The Clinical Drug contained in the packaged product.   

Discussion

The 

For packaged clinical drug concepts, the

For Combination (Packaged Medicinal) Products, there will be one Clinical Drug for each of the components in the packaged product that is placed into the supply chain. When a non-therapeutically active component such as a diluent is provided in a packaged medicinal product placed into the supply chain, extensions may choose whether to describe the diluent as a separate Clinical Drug or whether to manage the inclusion of the diluent in the product name only (see below in section 11)real packaged clinical drug concepts, the

As noted in the attribute tables for packaged clinical drug and real packaged clinical drug, it is not possible currently to explicitly specify an expression to describe the range of (real) clinical drugs to populate this attribute since (for example) a range cannot currently recognise a set of concepts with a particular semantic tag.  Alternative range expressions could be developed based on the attributes that are unique to a (real) clinical drug.  For example:

• For clinical drugs: all products with a dose form, precise ingredient substance, and basis of strength substance
• For real clinical drugs:  all products with a dose form, precise ingredient substance, basis of strength substance, product name, and supplier name.

Has pack size and Has pack size unit

Definition

Has pack size: The amount or quantity of clinical drug present in the package

Has pack size unit: The unit of measure appropriate for the pack size

Discussion

For (real) . For clinical drugs described with a unit of presentation and either a presentation strength or and concentration and presentation strength, the pack size reflects the number of units of presentation present in the package, and the pack size unit relates to the unit of presentation; for .  For (real) clinical drugs with a continuous presentation, this dose form, described with concentration strength, the pack size is the amount of the clinical drug present in the package with pack size units of either weight or volume as appropriate.

The following table describes some patterns and gives examples:

Note for those liquid products described using concentration strength,  the size of the intimate container is not described (a 1.5mL cartridge or a 3 mL cartridge). For liquid products presented in an intimate container described using a concentration strength, the volume of clinical drug present in the intimate container may need to be described separately. This could be achieved using "unit of presentation volume" and "unit of presentation volume units" attributes and values if this were required.

Count of clinical drug type

Packs of medicinal products must be represented using the closed world view; they contain only the clinical drug type(s) content stated.  In order to ensure that pack concepts classify correctly, so that packs that contain more than one (type of) clinical drug (i.e. combination packs) do not classify as children of packs that contain only one type of clinical drug, a "count of clinical drug type" attribute is used. 

Standard packs containing a single clinical drug type have a count of "one" for the "count of clinical drug type attribute".

Combination packs have the appropriate count (always greater than one) for the number of clinical drug types present in the combination pack. If one of the components of a combination pack is a therapeutically inactive diluent, national extensions can choose whether to include this in the "count of clinical drug" and therefore whether the pack containing the diluent will classify as a sibling or as a child of any pack not containing a diluent. See also section 11 below.

(Outer) Container

Description of the container that forms the outer package (the box, bottle, tube or jar) is not considered to be a definitional attribute for the Packaged Clinical Drug or Real Packaged Clinical Drug classes; no use cases have been presented to date to require this as a definitional attribute.  However, national extensions may have a use for the information, possibly even with dimensions, to support robotic dispensing and supply chain use cases, using reference sets and/or additional axiom functionality.  

...